Broadening Our Expectations for Viral Safety Risk Mitigation

Ivar J. Kljavin

doi:10.5731/pdajpst.2011.00833

OtherConference Proceeding

Broadening Our Expectations for Viral Safety Risk Mitigation

Ivar J. Kljavin

PDA Journal of Pharmaceutical Science and Technology November 2011, 65 (6) 645-653; DOI: https://doi.org/10.5731/pdajpst.2011.00833

Ivar J. Kljavin

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
References
Info & Metrics
PDF

Article Information

vol. 65 no. 6 645-653

DOI

https://doi.org/10.5731/pdajpst.2011.00833

PubMed

22294591

Published By

Parenteral Drug Association (PDA)

Print ISSN

1079-7440

Online ISSN

1948-2124

History

Published online January 4, 2012.

Author Information

Ivar J. Kljavin

Genentech, Quality Control Virus and Mycoplasma

Ivar J. Kljavin, Genentech, A member of the Roche Group, Quality Control Virus and Mycoplasma. E-mail: kljavin.ivar{at}gene.com.

View Full Text

Cited By...

3 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

Considerations for risk and control of mycoplasma in bioprocessing

Phillip Angart, Casey Kohnhorst, Meng-Jung Chiang, Nilou Sarah Arden

Current Opinion in Chemical Engineering 2018 22
Impacts of intentional mycoplasma contamination on CHO cell bioreactor cultures

Erica J. Fratz‐Berilla, Talia Faison, Casey L. Kohnhorst, Sai Rashmika Velugula‐Yellela, David N. Powers, Kurt Brorson, Cyrus Agarabi

Biotechnology and Bioengineering 2019 116 12
Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events

Erica J. Fratz‐Berilla, Phillip Angart, Ryan J. Graham, David N. Powers, Adil Mohammad, Casey Kohnhorst, Talia Faison, Sai Rashmika Velugula‐Yellela, Nicholas Trunfio, Cyrus Agarabi

Biotechnology and Bioengineering 2020 117 9

PreviousNext

In This Issue

PDA Journal of Pharmaceutical Science and Technology

Vol. 65, Issue 6

November/December 2011

Table of Contents
Index by Author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Broadening Our Expectations for Viral Safety Risk Mitigation

Message Subject (Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology

Message Body (Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 2 + 12 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Broadening Our Expectations for Viral Safety Risk Mitigation

Ivar J. Kljavin

PDA Journal of Pharmaceutical Science and Technology Nov 2011, 65 (6) 645-653; DOI: 10.5731/pdajpst.2011.00833

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Broadening Our Expectations for Viral Safety Risk Mitigation

Ivar J. Kljavin

PDA Journal of Pharmaceutical Science and Technology Nov 2011, 65 (6) 645-653; DOI: 10.5731/pdajpst.2011.00833

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
References
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Conference Proceeding

Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies
Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation
Proceedings of the 2017 Viral Clearance Symposium: Conclusion

Show more Conference Proceeding

Plenary Session 5: Viral Testing: Existing Assays and Emerging Technologies

Current Testing Methods and Challenges for Detection of Adventitious Viruses
Overview of Emerging Technologies To Detect Adventitious Agents
Theory and Practice of Conventional Adventitious Virus Testing

Show more Plenary Session 5: Viral Testing: Existing Assays and Emerging Technologies

Paper

Current Testing Methods and Challenges for Detection of Adventitious Viruses
Overview of Emerging Technologies To Detect Adventitious Agents
Theory and Practice of Conventional Adventitious Virus Testing

Show more Paper

Main menu

User menu

Search

Broadening Our Expectations for Viral Safety Risk Mitigation

Article Information

Author Information

Cited By...

In This Issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Conference Proceeding

Plenary Session 5: Viral Testing: Existing Assays and Emerging Technologies

Paper

Similar Articles

Readers

Author/Reviewer Information

Parenteral Drug Association, Inc.